Company: STAA
Filing Date: 2025-10-07
Form Type: DFAN14A
Source: 0001213900-25-097083
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-07
Form: DFAN14A
Chunk 1
---

October 23, 2025 (including any adjournments, postponements, reschedulings or continuations thereof, the “Special Meeting”).
The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) and accompanying GREEN Proxy
Card to be used in connection with any such solicitation of proxies from the Company’s stockholders for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURTIES AND EXCHANGE COMMISSION (THE “SEC”) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND additional information relating to the Participants and their direct or indirect interests, by security holdings or otherwise. The Definitive
Proxy Statement and accompanying GREEN Proxy Card have been furnished to some or all of the Company’s stockholders
and will be, along with other relevant documents, available at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on September 26, 2025 and is available here.

Exhibit 1

Exhibit 2

<div align='center'>Yunqi Capital, One of STAAR Surgical Company’s

Largest Shareholders, Reiterates Its Opposition to the

Proposed Merger with Alcon

STAAR Continues to Significantly Underestimate the Strength of the Business

and Future Prospects and Misrepresent Its Performance, Competitive Position, and Market Penetration

Incentives for STAAR’s CEO Are Not Aligned with Shareholders

Shareholders Should Preserve the Value of Their Investment and Vote Against the Proposed Merger</div>

HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ:STAA), today released the following open letter reiterating its opposition to the proposed sale to Alcon Inc. (SIX/NYSE: